A

Atea Pharmaceuticals
D

AVIR

3.38000
USD
0.07
(2.11%)
مغلق
حجم التداول
19,481
الربح لكل سهم
0
العائد الربحي
-
P/E
-2
حجم السوق
289,258,626
أصول ذات صلة
AZN
AZN
-0.110
(-0.16%)
70.530 USD
BNTX
BNTX
1.950
(1.89%)
105.060 USD
GSK
GSK
0.430
(1.12%)
38.690 USD
I
INO
0.12500
(6.48%)
2.05500 USD
JNJ
JNJ
0.895
(0.59%)
152.190 USD
MRK
MRK
0.150
(0.19%)
80.350 USD
MRNA
MRNA
1.110
(4.32%)
26.790 USD
N
NVAX
0.17500
(2.77%)
6.49500 USD
PFE
PFE
0.280
(1.17%)
24.310 USD
المزيد
الأخبار المقالات

العنوان: Atea Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).